CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Stomach Cancer

  • Common Acid Reflux Drugs Could More Than Double Your Risk Of Stomach Cancer

    facebook Share on Facebook

    A new study found that long-term use of acid reflux and heartburn drugs can increase stomach cancer risks by almost 250%, NY Daily reports.

    Known as “proton pump inhibitors,” or PPIs, these commonly prescribed drugs are the go-to-fix for an overproduction of stomach acids. But for a small percentage of people who carry a bacterium called Helicobacter pylori, the risk of developing stomach cancer shoots up when they take a PPI for an extended period of time, according to the study. While half of the world’s population has this bacteria naturally occurring inside of them, for some, the combination of bacteria and PPIs is shown to lead to the development of stomach cancer.

  • Potent Anticancer Effects of Bioactive Mushroom Extracts (Phellinus linteus) on a Variety of Human Cancer Cells📎

    facebook Share on Facebook
    Abstract Title:
    ico

    Potent Anticancer Effects of Bioactive Mushroom Extracts (Phellinus linteus) on a Variety of Human Cancer Cells.

    Abstract Source:

    J Clin Med Res. 2015 Feb ;7(2):76-82. Epub 2014 Nov 19. PMID: 25436023

    Abstract Author(s):

    Sensuke Konno, Kevin Chu, Nicholas Feuer, John Phillips, Muhammad Choudhury

    Article Affiliation:

    Sensuke Konno

    Abstract:

    BACKGROUND:Although several therapeutic options are currently available for patients with various cancers, the outcomes are often disappointing and a more effective modality needs to be promptly established. We have been exploring an alternative approach using natural agents and two bioactive mushroom extracts isolated from Phellinus linteus (PL), namely PL-ES and PL-I-ES, were of our interest. As anticancer effects of similar extracts have been reported in several cancers, we investigated whether PL-ES and PL-I-ES might have such anticancer activities on a variety of human cancer cells in vitro.

    METHODS:Ten different types of human cancer cell lines, including three metastatic prostate, bladder, kidney, lung, breast, stomach, liver, and brain cancer cells, were employed and tested with PL-ES or PL-I-ES. Cell growth/viability, exertion of oxidative stress, and induction of apoptosis were assessed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay, lipid peroxidation (LPO) assay, and specific enzymatic assay, respectively.

    RESULTS:PL-ES (100µg/mL) exhibited potent anticancer activity, resulting in a significant (40-80%) growth reduction in all 10 cancer cells at 72 hours. PL-I-ES (100 µg/mL) was effective on only four cancer cells but its higher concentration at 250 µg/mL led to a significant (25-90%) growth reduction in seven cancer cells. LPO assays indicated that such a significant growth reduction by PL-ES (100 µg/mL) or PL-I-ES (100 or 250 µg/mL) could result from cell death due to a cytotoxic effect of oxidative stress (through free radicals). Moreover, enzymatic assays for caspase-3 (Csp-3) and caspase-9 (Csp-9), thepro-apoptotic regulators, showed that both enzymes were significantly activated by PL-ES or PL-I-ES, indicating that cell death due to oxidative stress was more likely associated with apoptosis.

    CONCLUSIONS:The present study shows that both PL-ES and PL-I-ES indeed have anticancer effects on a variety of cancer cells, although PL-ES appears to be more potent than PL-I-ES. Such an anticancer effect is presumably attributed to oxidative stress, which will ultimately lead to apoptosis. Therefore, these two bioactive mushroom extracts may have clinical implications in a more effective therapeutic option for a variety of human malignancies.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.